An Algerian pharmaceuticals company, Saïdal, has abandoned plans for a joint venture with Danish laboratory Novo Nordisk to build an insulin factory, Upline Securities reported.
Saïdal claims that it has the technical capabilities to produce the insulin on commercial scales without foreign input, but it is still awaiting a "political decision" before it can embark on production.
The company also claims that its eye, ear, and nose-drop factory in Algiers is being prevented from opening in order to protect an import market worth $40 million, said the company's news service – Albawaba.com
© 2001 Al Bawaba (www.albawaba.com)
